Neoadjuvant chemotherapy for early breast cancer
We congratulate the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) on - their important meta-analysis.1 Neoadjuvant chemotherapy (NACT) has become an important - tool and strategy for patients with breast cancer. Although NACT was traditionally - used in patients with locally advan...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
28 February 2018
|
| In: |
The lancet. Oncology
Year: 2018, Jahrgang: 19, Heft: 3, Pages: e129 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(18)30118-9 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/S1470-2045(18)30118-9 Verlag: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30118-9/abstract 
|
| Verfasserangaben: | David Krug, Sibylle Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1681752492 | ||
| 003 | DE-627 | ||
| 005 | 20220817023611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191113s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(18)30118-9 |2 doi | |
| 035 | |a (DE-627)1681752492 | ||
| 035 | |a (DE-599)KXP1681752492 | ||
| 035 | |a (OCoLC)1341250761 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Krug, David |e VerfasserIn |0 (DE-588)1062940202 |0 (DE-627)807054747 |0 (DE-576)420297944 |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant chemotherapy for early breast cancer |c David Krug, Sibylle Loibl |
| 264 | 1 | |c 28 February 2018 | |
| 300 | |a 1 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.11.2019 | ||
| 520 | |a We congratulate the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) on - their important meta-analysis.1 Neoadjuvant chemotherapy (NACT) has become an important - tool and strategy for patients with breast cancer. Although NACT was traditionally - used in patients with locally advanced breast cancer, with the aim of downstaging - and achieving operability, monitoring treatment response for prognostic purposes and - for risk stratification has become routine in current practice. | ||
| 700 | 1 | |a Loibl, Sibylle |e VerfasserIn |0 (DE-588)12433024X |0 (DE-627)085790508 |0 (DE-576)294122753 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Oncology |d London : The Lancet Publ. Group, 2000 |g 19(2018), 3, Seite e129 |h Online-Ressource |w (DE-627)325349770 |w (DE-600)2035574-9 |w (DE-576)100517544 |x 1474-5488 |7 nnas |a Neoadjuvant chemotherapy for early breast cancer |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:3 |g pages:e129 |g extent:1 |a Neoadjuvant chemotherapy for early breast cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(18)30118-9 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30118-9/abstract |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191113 | ||
| 993 | |a Editorial | ||
| 994 | |a 2018 | ||
| 998 | |g 1062940202 |a Krug, David |m 1062940202:Krug, David |d 910000 |d 911400 |e 910000PK1062940202 |e 911400PK1062940202 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1681752492 |e 3539489061 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Neoadjuvant chemotherapy for early breast cancer","title":"Neoadjuvant chemotherapy for early breast cancer"}],"language":["eng"],"person":[{"role":"aut","given":"David","display":"Krug, David","family":"Krug"},{"role":"aut","family":"Loibl","display":"Loibl, Sibylle","given":"Sibylle"}],"name":{"displayForm":["David Krug, Sibylle Loibl"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"28 February 2018"}],"recId":"1681752492","note":["Gesehen am 13.11.2019"],"relHost":[{"disp":"Neoadjuvant chemotherapy for early breast cancerThe lancet. Oncology","recId":"325349770","language":["eng"],"titleAlt":[{"title":"The lancet <London> / Oncology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["0.2000 -"],"origin":[{"publisherPlace":"London","dateIssuedKey":"2000","dateIssuedDisp":"2000-","publisher":"The Lancet Publ. Group"}],"title":[{"partname":"Oncology","title_sort":"lancet","title":"The lancet"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"19","text":"19(2018), 3, Seite e129","pages":"e129","year":"2018","issue":"3","extent":"1"},"id":{"eki":["325349770"],"zdb":["2035574-9"],"issn":["1474-5488"]},"note":["Gesehen am 22.09.2021"]}],"physDesc":[{"extent":"1 S."}],"id":{"doi":["10.1016/S1470-2045(18)30118-9"],"eki":["1681752492"]},"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a KRUGDAVIDLNEOADJUVAN2820 | ||